Julien's primer of drug action: a comprehensive guide to the actions, uses, and side effects of psychoactive drugs
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
New York, NY
Worth Publ.
2014
|
| Ausgabe: | 13th ed., 40th anniversary ed. |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Getrennte Zählung Ill., graph. Darst. |
| ISBN: | 9781464111716 1464111715 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV041644763 | ||
| 003 | DE-604 | ||
| 005 | 20140710 | ||
| 007 | t | ||
| 008 | 140212s2014 ad|| |||| 00||| eng d | ||
| 020 | |a 9781464111716 |9 978-1-4641-1171-6 | ||
| 020 | |a 1464111715 |9 1-4641-1171-5 | ||
| 035 | |a (OCoLC)884285544 | ||
| 035 | |a (DE-599)BVBBV041644763 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-473 | ||
| 050 | 0 | |a RM315 | |
| 082 | 0 | |a 615.788 |2 22 | |
| 084 | |a XI 5803 |0 (DE-625)153018:12909 |2 rvk | ||
| 084 | |a CHE893f |2 stub | ||
| 084 | |a MED941f |2 stub | ||
| 100 | 1 | |a Advokat, Claire D. |e Verfasser |0 (DE-588)1053480512 |4 aut | |
| 245 | 1 | 0 | |a Julien's primer of drug action |b a comprehensive guide to the actions, uses, and side effects of psychoactive drugs |c Claire D. Advokat ; Joseph E. Comaty ; Robert M. Julien |
| 246 | 1 | 3 | |a Primer of drug action |
| 250 | |a 13th ed., 40th anniversary ed. | ||
| 264 | 1 | |a New York, NY |b Worth Publ. |c 2014 | |
| 300 | |a Getrennte Zählung |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 0 | |a Psychopharmacology | |
| 650 | 0 | |a Psychotropic drugs | |
| 650 | 0 | |a Psychotropes | |
| 650 | 0 | |a Psychopharmacologie | |
| 650 | 4 | |a Psychopharmacologie | |
| 650 | 4 | |a Psychotropes | |
| 650 | 4 | |a Psychopharmacology | |
| 650 | 4 | |a Psychotropic Drugs |x pharmacology | |
| 650 | 4 | |a Psychotropic Drugs |x therapeutic use | |
| 650 | 4 | |a Psychotropic drugs | |
| 650 | 0 | 7 | |a Psychopharmakologie |0 (DE-588)4176249-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Psychopharmakon |0 (DE-588)4047729-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Wirkung |0 (DE-588)4190021-2 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Psychopharmakologie |0 (DE-588)4176249-6 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Psychopharmakon |0 (DE-588)4047729-0 |D s |
| 689 | 1 | 1 | |a Wirkung |0 (DE-588)4190021-2 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Comaty, Joseph E. |e Verfasser |0 (DE-588)1053480741 |4 aut | |
| 700 | 1 | |a Julien, Robert M. |e Verfasser |0 (DE-588)172172918 |4 aut | |
| 856 | 4 | 2 | |m Digitalisierung UB Bamberg - ADAM Catalogue Enrichment |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=027085490&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-027085490 | ||
Datensatz im Suchindex
| _version_ | 1804151869547741184 |
|---|---|
| adam_text | Contents
Preface
xv
Part
1
Introduction to Psychopharmacology: Biological
Basis of Drug Action 1
Jj The Neuron, Synaptic Transmission, and
Neurotransmitters
з
Overall Organization of the Brain
/
Overview of Synaptic Transmission
/
Specific
Neurotransmitters
/
Biogenic (Monoaminergic)
Neurotransmitters; Catecholamine
Transmitters: Dopamine and Norepinephrine; The Indolamine Transmitter: Serotonin;
Amino
Acid
Neurotransmitters; Peptide Neurotransmitters
Pharmacokinetics: How Drugs Are Handled by the Body
31
Drug Absorption; Oral Administration; Rectal Administration; Administration by
Inhalation; Administration Through Mucous Membranes; Administration Through
the Skin; Administration by Injection
/
Drug Distribution; Action of the Bloodstream;
Body Membranes That Affect Drug Distribution
/
Termination of Drug Action; Role
of the Kidneys in Drug Elimination; Role of the Liver in Drug Metabolism
/
Factors
Affecting Drug
Biotransformation;
Other Routes of Drug Elimination
/
Time Course
of Drug Distribution and Elimination: Concept of Drug Half-Life
/
Drug Half-Life,
Accumulation, and Steady State
/
Therapeutic Drug Monitoring
/
Drug Tolerance
and Dependence
Pharmacodynamics; How Drugs Act
65
Receptors for Drug Action; Receptor Structure; Drug-Receptor Specificity; Acute
and Chronic Receptor Effects
/
Dose-Response Relationships
/
Variability in Drug
Responsiveness
—
The Therapeutic Index; Drug Interactions; Drug
Toxicity;
Placebo
Effects: Powerful or Problematic?
VII
VIII CONTENTS
Part
2
Pharmacology of Drugs of Abuse
93
Epidemiology and Neuiobiology of Addiction
95
Extent of the Drug Problem
/
Nosology and Psychopathology of Substance
Abuse
/
Neurobiology of Addiction; Introduction; Common Effects of Abused Drugs
on Brain Reward Circuits; From Abuse to Addiction; Glutamatergic Substrates
of Addiction
/
Introduction to Epigenetics; Structure of the Genome; Epigenetic
Function; Epigenetic Effects; Epigenetic Influences in Addiction
/
Pharmacotherapy
of Substance Use Disorders; Agonist Substitution Treatment; Partial Agonist
Substitution Treatment; Antagonists as Treatments for Addiction; Targeting
Nondopaminergic
Neurotransmitter
Systems
/
New Directions
Ethy! Alcohol ana the Inhalants of Abuse
125
ETHYLALCOHOL
Pharmacokinetics of Alcohol; Absorption; Distribution; Metabolism and
Excretion
/
Pharmacodynamics;
Glutamate
Receptors;
GABA
Receptors; Opioid
Receptors; Serotonin Receptors; Cannabinoid Receptors
/
Pharmacological
Effects
/
Psychological Effects
/
Tolerance and Dependence
/
Side Effects and
Toxicity
/
Teratogenic Effects
/
Alcoholism and Its Pharmacological Treatment;
Pharmacotherapies for Alcohol Abuse and Dependence; Pharmacotherapies
for Management of Alcohol Withdrawal; Pharmacotherapies to Help Maintain
Abstinence and Prevent Relapse; COMBINE Study; Pharmacotherapies to Help Treat
Comorbid Psychological Conditions
INHALANTS OF ABUSE
Why Inhalants Are Abused and Who Abuses Them
/
Consequences of Acute Use of
Inhalants
/
Long-Term
Consequences of Chronic Inhalant Abuse
Chapter
5
Appendix: What Is a Drink? How Much
Alcohol Is in Your Drink?
165
Caffeine and Nicotine
167
CAFFEINE
Pharmacokinetics
/
Pharmacological Effects; Beneficial Effects of Caffeine; Adverse
Effects of Caffeine
/
Mechanism of Action
/
Reproductive Effects
/
Tolerance and
Dependence
NICOTINE
Epidemiology and Public Policy
/
Pharmacokinetics
/
Mechanism of
Action
/
Pharmacological Effects
/
Effects on the Brain; Acute Effects on
the Body
/
Tolerance and Dependence
/
Toxicity;
Cardiovascular Disease;
Pulmonary Disease; Cancer
/
Effects of Passive Smoke
/
Effects During
Pregnancy
/
Pharmacological Therapies for Nicotine Dependence; Nicotine
Replacement Therapies; Partial Nicotinic Agonists; Vaccine Therapy
CONTENTS
IX
Cocaine, the Amphetamines, and
Other
Psychostimulants
201
COCAINE
History
/
Forms of Cocaine
/
Pharmacokinetics; Absorption; Distribution;
Metabolism and Excretion
/
Mechanism of Action
/
Pharmacological Effects in
Human Beings
/
Comorbidity
/
Cocaine and Pregnancy
AMPHETAMINES
History
/
Pharmacokinetics of Amphetamine Compared with Cocaine
/
Mechanism
of Action
/
Pharmacological Effects
/
Methamphetamine; Pharmacokinetics;
Neurotoxicity; Effects in Pregnancy; Dependence and Tolerance
NONAMPHETAMINE BEHAVIORAL STIMULANTS
Synthetic Cathinones ( Bath Salts )
/
Pharmacological Treatment of Stimulant
Dependency; Dopaminergic/Adrenergic Treatment Approaches; GABAergic/
Glutamatergic Treatment Approaches; Pharmacokinetic Approaches to
Psychostimulant
Abuse
—
Metabolizing Enzymes; Pharmacokinetic Approaches to
Psychostimulant
Abuse
—
Vaccines
Psychedelic Drugs
237
Scopolamine:
The Prototype Anticholinergic (ACh) Psychedelic; Historical
Background; Pharmacological Effects
/
Monoaminergic Psychedelics
/
Catecholaminergic Psychedelics;
Mescaline;
Synthetic Amphetamine
Derivatives; MDMA: The Prototype Catecholamine Psychedelic; MDMA Related
Substances; Myristicin and
Elemicin
/
Serotonergic Psychedelics; Lysergic Acid
Diethylamide: The Prototype Serotonergic Psychedelic; Other Serotoninlike
Hallucinogens
/
Glutaminergic NMDA Receptor Antagonists; Phencyclidine and
Ketamine; Methoxetamine; Dextromethorphan (DXM)
/
Salvinorin A; Mechanism of
Action; Potential Therapeutic Uses of Salvinorum Derivatives
_9_
Cannabis
267
Epidemiology
/
History
/
What Is
Cannabis?
/
Mechanism of Action: Cannabinoid
Receptors
/
Endocannabinoids
/
Pharmacokinetics
/
Pharmacological Effects of
Cannabis;
Acute and Chronic Physiological Effects; Acute and Chronic Psychoactive
Effects
/
Tolerance and Dependence
/
Treatment Issues
/
Synthetic Cannabinoid
Agonists of Abuse: Herbal Marijuana Alternatives (HMAs); Classes of Synthetic
Cannabinoid Drugs; Current Abuse; Pharmacological, Physiological, Psychoactive
Effects and
Toxicity
8
CONTENTS
[τ
(ij Opioid
Analgesics
297
Pain
Terminology; Pain Signaling / History
/
Opioid
Terminology
/
Opioid
Receptors /Classification of Opioids Pure Agonists; Partial Agonists; Mixed Agonist-
Antagonists; Pure Antagonists
/
Major Pharmacological Effects of Opiates
/
Genetic
Opioid Metabolic Defects (GOMD)
/
Tolerance and Dependence
/
Prescription
Opioid Abuse
/
Common Opiate Drugs Morphine: A Pure Opioid Agonist; Codeine;
Heroin; Hydrocodone and Oxycodone; Hydromorplione and Oxymorphone;
Propoxyphene; Meperidine; Fentanyl and Its Derivatives; Tramadol;
Tupen
tadol
(Nucynta); Mixed Agonist-Antagonist Opioids; Methadone; LAAM; Buprenorphine;
Pure Opioid Antagonists
/
Novel Opioid Compounds Under Development
/
Future
Pharmacotherapy of Opioid Dependence
/
Illicit Opiates of Abuse
Part
3
11
Psychotherapeutic Drugs
335
Antipsychotic Drugs
337
Schizophrenia; Dopamine Involvement; Serotonin Involvement;
Glutamate
Involvement
HISTORICAL BACKGROUND AND CLASSIFICATION OF ANTIPSYCHOTIC
DRUGS
CATIE and CUtLASS Studies
/
First-Generation Antipsychotic Drugs: FGAs;
Pharmacokinetics; Pharmacological Effects; Side Effects and
Toxicity;
Tolerance and
Dependence
/
Individual First-Generation Antipsychotics; Haloperidol; Molindone;
Loxapine; Pimozide
/
Second-Generation (Atypical) Antipsychotic Agents; Clozapine;
Risperidone; Olanzapine; Sertindole; Quetiapine; Ziprasidone; Aripiprazole;
Iloperidone; Asenapine; Lurasidone
/
Prominent Side Effects of Second-Generation
Antipsychotics; Weight Gain; Diabetes and Hyperglycemia; Electrocardiographs
Abnormalities (Sudden Cardiac Death)
/
New Agents and Updated Recommendations
for the Treatment of Schizophrenia
/
Additional Applications for Second-Generation
Antipsychotics; Bipolar Disorder; Unipolar Depression; Dementia; Autism Spectrum
Disorders, Pervasive Developmental Disorder, Agitation, and Aggression; Posttraumatic
Stress Disorder; Obsessive-Compulsive Disorder; Borderline Personality Disorder;
Parkinsons Disease
/
Experimental Agents and Future Developmental Efforts
12| Antidepressant Drugs
385
Depression; Pathophysiology of Depression; Evolution of Antidepressant Drug
Development
/
First-Generation Antidepressants; Tricyclic Antidepressants;
Monoamine
Oxidase
Inhibitors; The Treatment-Resistant Patient; Serotonin
Syndrome; SSRI Discontinuation Syndrome; SSRI-Induced Sexual Dysfunction;
Additional Side Effects of SSRIs; Specific SSRIs
/
Atypical Antidepressants
/
Selective
Serotonin Reuptake Inhibitors (SSRIs)
/
Dual-Action Antidepressants; Nefazodone;
Milnacipran; Venlafaxine; Desvenlafaxine; Duloxetine; Mirtazepine
/
Selective
Norepinephrine Reuptake Inhibitors
/
STAR*D Study; Results; Conclusions; Where Do
We Go From Here in Antidepressant Treatment?; Genetic Influences
/
Antidepressants
13
14
CONTENTS
XI
of the Future: More Effective? Fewer Side Effects?; Augmenting Agents; Serotonin
Receptor Partial Agonists; Natural Substances That May have Antidepressant
Properties
/
Ketami
ne
and Other Glutaminergic Agonists
/
Miscellaneous Agents with
Potential Antidepressant Actions
Chapter
12
Appendix: Drugs for the Treatment of Obesity
430
Sedative-Hypnotic and Anxiolytic Medications
433
Historical Background
/
Sites and Mechanisms of Action
/
Sedative-Induced
Brain Dysfunction
/
Barbiturates; Pharmacokinetics; Pharmacological Effects;
Psychological Effects; Clinical Uses; Adverse Reactions; Tolerance; Physical Dependence;
Effects in Pregnancy
/
Nonbarbiturate Sedative-Hypnotic Drugs
/
Benzodiazepines;
Pharmacokinetics; Pharmacological Effects; Clinical Uses and Limitations; Side
Effects and
Toxicity;
Tolerance and Dependence; Effects in Pregnancy
/
Flumazenil: A
Benzodiazepine Receptor Antagonist
/
Benzodiazepine Receptor Agonist (BZRA)
Hypnotics; Benzodiazepine BZRAs; Nonbenzodiazepine BZRAs; Partial Agonists at
GABAa Receptors; Sleep Driving and Sleep-Related Activities; General Anesthetics;
Ramelteon:
A Selective Melatonin Receptor Agonist; Agomelatine: Another Selective
Melatonin Receptor Agonist; Orexin Antagonists for Insomnia
/
Serotonin Receptor
Agonists as Anxiolytics
/
Antiepileptic Drugs; Antiepileptic Drugs in Pregnancy;
Antiepileptic Drugs and Risk of Suicidal Thoughts and Behavior
Drugs Used to Treat Bipolar Disorder
467
Bipolar Disorder
/
Diagnostic and Treatment Issues; Bipolar versus Unipolar
Depression; Pathophysiology and Mechanisms of Drug Action
/
STEP-BD
Study
/
Mood Stabilizers: Lithium; Pharmacokinetics; Pharmacodynamics;
Side Effects and
Toxicity;
Effects in Pregnancy; Nonadherence; Combination
Therapy; LiTMUS Study
/
Mood Stabilizers: Neuromodulator Anticonvulsants;
Carbamazepine; Oxcarbazepine; Valproic Acid; Lamotrigine; Gabapentin and
Pregabalin; Topiramate; Zonisamide; Tiagabine
/
Other Uses for Anticonvulsant
Mood Stabilizers; Neuropathic Pain; Anxiety Disorders; Borderline Personality
Disorder
/
Atypical Antipsychotics for Bipolar Disorder; Acute Mania; Maintenance
of Remission; Bipolar Depression
/
Omega-3 Fatty Acids for Bipolar Disorder;
Miscellaneous Agents
/
Psychotherapeutic and
Psychosocial
Treatments
Part
4
15
Special Populations and Integration
505
Child and Adolescent Psychophaimacology
507
PREGNANCY AND PSYCHOTROPIC DRUGS
Antidepressants in the Pregnant Female and Neonatal Outcomes
/
Mood Stabilizers
in the Pregnant Female and Neonatal Outcomes
/
Atypical Antipsychotics in the
Pregnant Female and Neonatal Outcomes
XII CONTENTS
PRESCHOOL PSYCHOPHARMACOLOGY
Medications for Treating Attention Deh cit/Hyperactivity Disorder (ADHD) in Very
Young Children
/
Medications for Treating Disruptive Behaviors in Very Young
Children
/
Medications for Treating Depression in Very Young Children
/
Medications
for Treating Bipolar Disorder in Very Young Children
/
Medications for Treating
Anxiety Disorders in Very Young Children
/
Medications for Treating Autism
Spectrum Disorders in Very Young Children
CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
Medications lor Treating Autism Spectrum Disorders (ASD)
/
Medications
for Treating Behavioral or Aggressive Disorders
/
Medications for Treating
ADHD; Guidelines for Management of ADHD; Stimulant Treatment for ADHD;
Methylphenidate; Amphetamines; Alternative Medications for Treating ADHD;
Side Effects of Stimulant Medications
/
Medications and Medical Issues in Treating
Depression Alternative Medications and Treatments; Antidepressants and Suicidal
Ideation; Guidelines for Adolescent Depression for Primary Care (GLAD-PC); Calls
for Widespread Screening for Youth at Risk
/
Medications for Treating Anxiety
Disorders
/
Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder
(SAD), and Social Phobia (SoP); Obsessive-Compulsive Disorder; Posttraumatic
Stress Disorder (PTSD); Panic Disorder
/
Medications for Treating Bipolar
Disorder
/
Medications for Treating Psychotic Disorders
17
16
Geriatric
Psychopharmacology
555
Inappropriate Drug Use in the Elderly
/
Control of Agitated and Aggressive
Behaviors in the Elderly
/
Undertreatment of the Elderly: Focus on Depression;
Antidepressants to Treat Depression in the Elderly
/
Parkinson s Disease; Levodopa;
COMT Inhibitors; Dopamine Receptor Agonists; Selective Monoamine Oxidase-B
Inhibitors; Muscarinic Receptor Antagonists;
Amantadme
and Memantine; New
Approaches in the Pipeline; Alzheimer s Disease; Acetylcholinesterase Inhibitors
(AChE-Is); Memantine
/
New Treatment Approaches: The Pipeline
/
Principles of
Care for Patients with Alzheimer s Disease
Challenging Times for Mental Health
591
Epidemiological Developments; Policy Developments
/
Clinical Developments:
Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
/
Questioning the
Efficacy of Psychotropic Medications
/
Pharmaceutical Developments
/
Integrating
Psychopharmacology and Psychological Therapies in Patient Care; Clinical
Examples2
/
Considerations for Current Practice
Chapter
17
Appendix: Quick Reference to
Psychotropic Medications
606
Glossary
с.·!
Index
и
CONTENTS Xlii
New
¡η
this Thirteenth Edition!
Did You Know? boxes highlight interesting and surprising facts or news related to the
chapter content.
Chapter
1
Obama s BRAIN Initiative
7
Growing New Neurons
12
Chapter
2
Drugs That Interact with Grape Fruit on the Rise
36
Improving Delivery of Medicines to the Brain
46
Chapter
3
Nocebo Effects
90
Chapter
4
Talking About Yourself Online Is as Rewarding to the Brain as
Sex or Eating
102
Decreased Dopamine In Addicted Brains
103
Chapter
5
Alcohol Is Directly Related to Four of the Top Ten Offenses in
the United States
137
Designated Drivers Don t Always Abstain
138
Rejected Male Fruit Flies Turn to Alcohol
139
Chapter
6
Lab Experiments Question Effectiveness of Green Coffee
Bean Weight-Loss Supplements
171
Tobacco Laws for Youth May Reduce Adult Smoking
177
Chapter
7
Skin Reactions to Adulterated Cocaine
207
Two-and-a-Half Years of Meth Abuse
/
Methamphetamine
216
Meth Mouth
/
Dependence and Tolerance
217
Chapter
8
Pont-Saint-Esprit
Poisoning: Did the CIA Spread LSD?
251
Chapter
9
Synthetic Marijuana Third Most Reported Substance Used by
U.S. High School Students
268
XIV CONTENTS
More Kids Exposed to Legal Pot?
277
Workers in Philadelphia Demolition Tragedy Allegedly High
on Marijuana
283
Chapter
10
Risks of Opiate Addiction
306
Numerous Well-Known Personalities Have Succumbed to Opiate
314
Chapter
11
Now We Know Why Old Schizophrenia Medicine Works On
Antibiotic-Resistant Bacteria
344
There May be a Way to Determine Which Patients Will Gain
Weight When Taking Antipsychotic Medications
362
Chapter
12
Mystery Biography
394
You Are—and Your Mood Is—What You Eat
421
Chapter
13
Brain s Own
Valium
Discovered
436
Dogs, Humans Affected by OCD Have Similar Brain Abnormalities
437
Chapter
14
MENTAL ILLNESS IN THE MOVIES: No Laughing Matter
468
Ebselen a Possible Lithium Mimic, Mouse Study Hints
494
Chapter
15
Doubling of Deaths Among Sick Moms-To-Be Amid Poor
Evidence On Drug Safety in Pregnancy
509
FDA Warns Against Valproate to Prevent Migraine in Pregnancy
515
Chapter
16
Map: Alzheimer s Disease Death Rate Per 100K Population
by U.S. State,
1999-2010 571
An Olive Oil Compound That Makes Your Throat Itch May
Prevent Alzheimer s
575
Cinnamon Compound Has Potential Ability to Prevent Alzheimer s
581
Chapter
17
Mortality Gap Widens for Mentally 111
/
Epidemiological
Developments
59 {
Treatment of Mental Illness Lowers Arrest Rates, Saves
Mone
593
|
| any_adam_object | 1 |
| author | Advokat, Claire D. Comaty, Joseph E. Julien, Robert M. |
| author_GND | (DE-588)1053480512 (DE-588)1053480741 (DE-588)172172918 |
| author_facet | Advokat, Claire D. Comaty, Joseph E. Julien, Robert M. |
| author_role | aut aut aut |
| author_sort | Advokat, Claire D. |
| author_variant | c d a cd cda j e c je jec r m j rm rmj |
| building | Verbundindex |
| bvnumber | BV041644763 |
| callnumber-first | R - Medicine |
| callnumber-label | RM315 |
| callnumber-raw | RM315 |
| callnumber-search | RM315 |
| callnumber-sort | RM 3315 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| classification_rvk | XI 5803 |
| classification_tum | CHE893f MED941f |
| ctrlnum | (OCoLC)884285544 (DE-599)BVBBV041644763 |
| dewey-full | 615.788 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.788 |
| dewey-search | 615.788 |
| dewey-sort | 3615.788 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie Medizin |
| edition | 13th ed., 40th anniversary ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02347nam a2200601 c 4500</leader><controlfield tag="001">BV041644763</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20140710 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">140212s2014 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781464111716</subfield><subfield code="9">978-1-4641-1171-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1464111715</subfield><subfield code="9">1-4641-1171-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)884285544</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV041644763</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-473</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM315</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.788</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 5803</subfield><subfield code="0">(DE-625)153018:12909</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">CHE893f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MED941f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Advokat, Claire D.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1053480512</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Julien's primer of drug action</subfield><subfield code="b">a comprehensive guide to the actions, uses, and side effects of psychoactive drugs</subfield><subfield code="c">Claire D. Advokat ; Joseph E. Comaty ; Robert M. Julien</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Primer of drug action</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">13th ed., 40th anniversary ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Worth Publ.</subfield><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Getrennte Zählung</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Psychopharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Psychotropic drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Psychotropes</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Psychopharmacologie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychopharmacologie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychotropes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychopharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychotropic Drugs</subfield><subfield code="x">pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychotropic Drugs</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychotropic drugs</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Psychopharmakologie</subfield><subfield code="0">(DE-588)4176249-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Psychopharmakon</subfield><subfield code="0">(DE-588)4047729-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Wirkung</subfield><subfield code="0">(DE-588)4190021-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Psychopharmakologie</subfield><subfield code="0">(DE-588)4176249-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Psychopharmakon</subfield><subfield code="0">(DE-588)4047729-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Wirkung</subfield><subfield code="0">(DE-588)4190021-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Comaty, Joseph E.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1053480741</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Julien, Robert M.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)172172918</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Bamberg - ADAM Catalogue Enrichment</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=027085490&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-027085490</subfield></datafield></record></collection> |
| id | DE-604.BV041644763 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T01:01:40Z |
| institution | BVB |
| isbn | 9781464111716 1464111715 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-027085490 |
| oclc_num | 884285544 |
| open_access_boolean | |
| owner | DE-473 DE-BY-UBG |
| owner_facet | DE-473 DE-BY-UBG |
| physical | Getrennte Zählung Ill., graph. Darst. |
| publishDate | 2014 |
| publishDateSearch | 2014 |
| publishDateSort | 2014 |
| publisher | Worth Publ. |
| record_format | marc |
| spelling | Advokat, Claire D. Verfasser (DE-588)1053480512 aut Julien's primer of drug action a comprehensive guide to the actions, uses, and side effects of psychoactive drugs Claire D. Advokat ; Joseph E. Comaty ; Robert M. Julien Primer of drug action 13th ed., 40th anniversary ed. New York, NY Worth Publ. 2014 Getrennte Zählung Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Psychopharmacology Psychotropic drugs Psychotropes Psychopharmacologie Psychotropic Drugs pharmacology Psychotropic Drugs therapeutic use Psychopharmakologie (DE-588)4176249-6 gnd rswk-swf Psychopharmakon (DE-588)4047729-0 gnd rswk-swf Wirkung (DE-588)4190021-2 gnd rswk-swf Psychopharmakologie (DE-588)4176249-6 s DE-604 Psychopharmakon (DE-588)4047729-0 s Wirkung (DE-588)4190021-2 s Comaty, Joseph E. Verfasser (DE-588)1053480741 aut Julien, Robert M. Verfasser (DE-588)172172918 aut Digitalisierung UB Bamberg - ADAM Catalogue Enrichment application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=027085490&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Advokat, Claire D. Comaty, Joseph E. Julien, Robert M. Julien's primer of drug action a comprehensive guide to the actions, uses, and side effects of psychoactive drugs Psychopharmacology Psychotropic drugs Psychotropes Psychopharmacologie Psychotropic Drugs pharmacology Psychotropic Drugs therapeutic use Psychopharmakologie (DE-588)4176249-6 gnd Psychopharmakon (DE-588)4047729-0 gnd Wirkung (DE-588)4190021-2 gnd |
| subject_GND | (DE-588)4176249-6 (DE-588)4047729-0 (DE-588)4190021-2 |
| title | Julien's primer of drug action a comprehensive guide to the actions, uses, and side effects of psychoactive drugs |
| title_alt | Primer of drug action |
| title_auth | Julien's primer of drug action a comprehensive guide to the actions, uses, and side effects of psychoactive drugs |
| title_exact_search | Julien's primer of drug action a comprehensive guide to the actions, uses, and side effects of psychoactive drugs |
| title_full | Julien's primer of drug action a comprehensive guide to the actions, uses, and side effects of psychoactive drugs Claire D. Advokat ; Joseph E. Comaty ; Robert M. Julien |
| title_fullStr | Julien's primer of drug action a comprehensive guide to the actions, uses, and side effects of psychoactive drugs Claire D. Advokat ; Joseph E. Comaty ; Robert M. Julien |
| title_full_unstemmed | Julien's primer of drug action a comprehensive guide to the actions, uses, and side effects of psychoactive drugs Claire D. Advokat ; Joseph E. Comaty ; Robert M. Julien |
| title_short | Julien's primer of drug action |
| title_sort | julien s primer of drug action a comprehensive guide to the actions uses and side effects of psychoactive drugs |
| title_sub | a comprehensive guide to the actions, uses, and side effects of psychoactive drugs |
| topic | Psychopharmacology Psychotropic drugs Psychotropes Psychopharmacologie Psychotropic Drugs pharmacology Psychotropic Drugs therapeutic use Psychopharmakologie (DE-588)4176249-6 gnd Psychopharmakon (DE-588)4047729-0 gnd Wirkung (DE-588)4190021-2 gnd |
| topic_facet | Psychopharmacology Psychotropic drugs Psychotropes Psychopharmacologie Psychotropic Drugs pharmacology Psychotropic Drugs therapeutic use Psychopharmakologie Psychopharmakon Wirkung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=027085490&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT advokatclaired juliensprimerofdrugactionacomprehensiveguidetotheactionsusesandsideeffectsofpsychoactivedrugs AT comatyjosephe juliensprimerofdrugactionacomprehensiveguidetotheactionsusesandsideeffectsofpsychoactivedrugs AT julienrobertm juliensprimerofdrugactionacomprehensiveguidetotheactionsusesandsideeffectsofpsychoactivedrugs AT advokatclaired primerofdrugaction AT comatyjosephe primerofdrugaction AT julienrobertm primerofdrugaction |